How to Request FDA Type B Meetings: Timelines, Formats, and Best Practices

Overview of FDA Type B Meetings

Type B meetings with the FDA are the most common form of formal interaction between sponsors and the agency during drug development. These meetings occur at key milestones such as pre-Investigational New Drug (pre-IND), end-of-Phase 2 (EOP2), and pre-New Drug Application (pre-NDA) stages. They are designed to facilitate regulatory alignment before major submissions and help sponsors avoid delays or rejections due to data gaps or compliance issues.

The FDA recognizes these meetings as essential checkpoints in the lifecycle of drug, biologic, or device development. To benefit from a Type B meeting, sponsors must adhere strictly to submission timelines and formatting requirements.

Types of Type B Meetings

• Pre-IND Meeting: Occurs before initial IND submission; allows review of study design and safety requirements.
• End-of-Phase 1 (EOP1): Used when significant changes are planned or to discuss early efficacy signals.
• End-of-Phase 2 (EOP2): Helps finalize Phase 3 design and confirm adequacy of safety/efficacy data.
• Pre-NDA/Pre-BLA: Ensures completeness of marketing application data before submission.

These meetings significantly influence approval timelines. Missing a Type B opportunity can result in poor submission outcomes or unnecessary study duplication.

Timeline for Requesting a Type B Meeting

According to the FDA’s guidance for industry, sponsors must follow specific timing rules for requesting Type B meetings:

• Meeting request submission: At least 60 days before the desired meeting date.
• FDA confirmation or denial: Within 14 calendar days of receiving the request.
• Scheduling: If accepted, FDA schedules the meeting within 60 calendar days from the receipt of the request.
• Briefing package submission: Must be provided at least 30 days before the confirmed meeting date.

Failing to adhere to this timeline can lead to delays or the meeting being declined altogether.

Continue with Submission Format, Meeting Examples, and FDA Process Flow

Formatting Your FDA Meeting Request

The meeting request should be submitted in eCTD format (if applicable) through the Electronic Submissions Gateway (ESG) and must include the following:

• Type of meeting requested (e.g., pre-IND Type B)
• Proposed agenda and list of questions, grouped by functional area
• Preferred dates and times (3–5 options)
• Participants from the sponsor and suggested FDA attendees (if known)
• Format of the meeting (face-to-face, teleconference, or written response only)
• Application number if available (IND/NDA/BLA)
• Cover letter and proposed meeting minutes template

Sponsors must be specific in their meeting objectives and questions to ensure focused and actionable FDA feedback.

Real-World Example: EOP2 Meeting Timeline

A sponsor developing a novel inhaled corticosteroid prepared for an end-of-Phase 2 meeting. The timeline followed:

• Meeting request submitted: March 1
• FDA response confirming meeting: March 10
• Meeting scheduled: April 29
• Briefing package submitted: March 29
• Meeting held via teleconference with CMC and clinical experts

The sponsor received critical guidance on PK comparability and finalized Phase 3 designs based on FDA’s feedback, enabling a smoother IND amendment and accelerated NDA preparation.

Best Practices for Submission and Scheduling

• Submit meeting requests electronically in the correct format using FDA ESG
• Ensure all questions are clear and provide background context
• Propose flexible dates and avoid public holidays or agency closure periods
• Prepare a response plan in case FDA offers Written Response Only (WRO)
• Assign a regulatory liaison to track communications and submissions

FDA’s Internal Process Flow for Type B Meetings

Interaction with Other Regulatory Milestones

Type B meetings should be strategically timed with:

• Submission of protocol amendments
• Initiation of Phase 3 studies
• CMC scale-up milestones
• Pre-NDA readiness checks

Aligning these meetings with development decisions reduces regulatory risk and avoids rework.

Where to Find Additional Guidance

Refer to Be Part of Research UK and FDA’s own Meeting Guidance Documents for templates and real-world case references that can improve your submission accuracy.

Conclusion: Timing and Clarity Are Everything

A timely and well-formatted FDA Type B meeting request can shape your regulatory pathway, prevent costly delays, and lead to successful product development outcomes. By understanding the timelines, structure, and internal FDA process, sponsors can position their programs for efficient advancement toward marketing applications.

Leveraging FDA Meeting Types for Strategic Regulatory Success

Introduction to FDA Meeting Types

The U.S. Food and Drug Administration (FDA) offers several types of formal meetings to help sponsors and applicants navigate the complex regulatory landscape. These meetings are not only regulatory checkpoints but also strategic tools that can streamline drug development and facilitate smoother submissions. Understanding when and how to request these meetings—especially the distinctions between Type A, Type B, and Type C—is crucial to maximizing their value.

These meetings apply across Investigational New Drug (IND), New Drug Application (NDA), Biologics License Application (BLA), and Abbreviated New Drug Application (ANDA) contexts. The primary objective is to obtain FDA feedback that guides development strategies and ensures regulatory compliance throughout the product lifecycle.

Type A Meeting: Addressing Critical Program Stoppages

A Type A meeting is the most urgent of the FDA’s meeting categories. It is typically reserved for resolving clinical holds, addressing disputes, or discussing necessary steps after the FDA has issued a refusal to file a marketing application.

Strategic Use: Sponsors use Type A meetings to seek guidance during major roadblocks in their development programs. Because this type of meeting is focused on immediate resolution, it must be requested with compelling justification and complete documentation of the issue at hand.

Timelines: FDA schedules Type A meetings within 30 calendar days of receiving the meeting request.

Type B Meeting: The Most Common and Strategic FDA Interaction

Type B meetings are the most frequently requested meetings and include:

• Pre-IND meetings
• End-of-Phase 1 (EOP1) and End-of-Phase 2 (EOP2) meetings
• Pre-NDA or Pre-BLA meetings

These meetings occur at critical junctures in the development lifecycle. For example, a pre-IND meeting helps shape the study design and regulatory expectations, while a pre-NDA meeting helps finalize submission strategies.

Strategic Value: These interactions help sponsors avoid costly errors, design better clinical studies, and clarify data expectations. A pre-NDA meeting, for instance, can validate whether your CMC and clinical data packages are complete.

Timelines: FDA will schedule Type B meetings within 60 calendar days of a valid request.

Type C Meeting: Addressing Everything Else

Type C meetings are more flexible and cover any topic not addressed by Type A or B meetings. These include:

• Clarification on statistical endpoints
• Questions on post-marketing studies
• Discussion on novel development approaches

Type C meetings are especially useful for emerging therapies and new technologies where the regulatory path may not be clearly defined.

Timelines: FDA schedules Type C meetings within 75 calendar days of receiving a complete meeting request.

Continue with Real-World Applications and Strategic Planning Tips

Real-World Use Cases: Strategic Deployment of FDA Meetings

Consider a scenario where a sponsor developing a gene therapy product encounters difficulty with vector design compatibility for long-term dosing. A Type C meeting allows the team to engage FDA experts in discussing novel preclinical models. Later, a pre-IND Type B meeting aligns their submission expectations and safety package for first-in-human studies.

In another case, an oncology sponsor uses a pre-NDA Type B meeting to confirm that their Phase 3 surrogate endpoints will support accelerated approval. This drastically shortens review timelines and avoids a potential Complete Response Letter (CRL).

Comparing Meeting Types: Strategic Implications

Meeting Request Components

A complete meeting request is essential for approval and scheduling. The request must include:

• Proposed meeting type and justification
• Product name and application type
• Proposed questions and goals of the meeting
• List of attendees (sponsor and FDA)
• Meeting format (teleconference, face-to-face, written response)

Sponsors should avoid vague or excessively broad meeting questions to ensure a focused and productive discussion.

Meeting Preparation: Regulatory Affairs Role

Regulatory Affairs plays a critical role in the following aspects:

• Drafting a well-structured briefing package
• Coordinating with SMEs across CMC, nonclinical, and clinical disciplines
• Simulating meeting Q&A sessions internally
• Ensuring all regulatory precedents are considered

According to ClinicalTrials.gov, engaging regulatory agencies early via Type B meetings improves submission quality and reduces delays.

Best Practices for Maximizing Meeting Value

• Frame questions clearly and contextually
• Provide a summary of development history
• Submit your briefing package at least 30 days before the meeting
• Assign internal note-takers and response coordinators
• Respect FDA’s time—avoid redundant queries

Post-Meeting Follow-Up and Documentation

FDA provides official meeting minutes within 30 days. However, sponsors should take internal notes, identify action items, and circulate summaries promptly. These insights feed into updated regulatory strategy documents and future meeting requests.

If FDA offers a Written Response Only (WRO), treat it with the same level of diligence and update your development plans accordingly.

Conclusion: Aligning Meeting Types with Development Goals

Understanding and strategically using the different FDA meeting types can unlock significant regulatory advantages. Whether resolving a critical issue via a Type A meeting or shaping your NDA through a Type B meeting, these opportunities must be approached with preparation, clarity, and a solid regulatory roadmap.

Strategies to Effectively Prepare for a Type B FDA Meeting

What Is a Type B Meeting and Why Is It Critical?

In the U.S. drug development process, structured communication with the Food and Drug Administration (FDA) is essential for aligning clinical, regulatory, and manufacturing strategies. Type B meetings are formal, scheduled interactions between sponsors and the FDA designed to address key development milestones, including Pre-IND meetings, End-of-Phase 2 meetings, and Pre-NDA/BLA meetings.

These meetings allow sponsors to clarify regulatory expectations, mitigate potential risks, and gain critical feedback before committing major resources to clinical trials or submission activities. Poor preparation, vague questions, or missing documents can derail the utility of the meeting and delay development timelines.

Sponsors also monitor global regulatory frameworks through platforms such as WHO ICTRP to understand precedents for similar meetings worldwide.

When to Request a Type B Meeting

The FDA recognizes the following as formal Type B meetings:

• Pre-IND Meeting: Before initial IND submission
• End-of-Phase 2 Meeting (EOP2): To discuss pivotal trial design
• Pre-NDA/BLA Meeting: To align on final submission strategy

These meetings are generally granted within 60 days of request, with meeting dates confirmed 21 days after FDA receives the initial request.

Preparing the Meeting Request

A successful FDA engagement starts with a clear and focused meeting request. This document should include:

• Purpose of the meeting and specific regulatory milestone
• Proposed agenda and list of discussion topics
• Draft questions to be addressed
• Preferred format (face-to-face, virtual, or written response)
• Brief background on the investigational product

Requests must be sent to the appropriate division electronically through the FDA’s CDER NextGen Portal or ESG.

Developing a High-Impact Briefing Package

The briefing package provides FDA reviewers with essential information to prepare for the meeting. It must be submitted no later than 30 days before the meeting and should include:

• Cover letter and executive summary
• Product overview, mechanism of action, and indication
• Clinical development history and status
• Nonclinical, CMC, and clinical data summaries
• Numbered, specific questions for FDA feedback

Sample Table: Draft Questions for a Type B Meeting

Execution, Documentation, and Post-Meeting Actions

Internal Preparation and Role Assignments

A well-coordinated internal preparation plan can make or break a Type B meeting. Sponsors should assign clear roles:

• Regulatory Lead: Owns the meeting agenda and communication with the FDA
• Clinical Lead: Responds to questions on trial design and endpoints
• CMC Lead: Addresses manufacturing, stability, and product quality queries
• Medical Monitor: Handles safety and adverse event strategy

Conduct a mock meeting or rehearsal to anticipate possible FDA follow-up questions, especially for End-of-Phase 2 meetings.

Conducting the Meeting: What to Expect

Type B meetings are typically 1 hour long and held via teleconference. The FDA project manager will lead the session, and FDA reviewers from relevant disciplines will participate.

Key tips:

• Stick to the agenda — time is limited
• Do not present lengthy slides unless requested
• Clarify ambiguities without debating FDA positions
• Take detailed notes and confirm FDA statements post-meeting

FDA Meeting Minutes and Their Importance

The FDA will issue official meeting minutes within 30 calendar days. These minutes are binding and should reflect the meeting’s discussions and conclusions accurately.

Sponsors should review the draft minutes carefully and request corrections within 7 calendar days if discrepancies exist.

Post-Meeting Actions and Alignment

After the meeting:

• Circulate minutes internally to align all stakeholders
• Document all decisions and rationale in the regulatory strategy file
• Update protocols, CMC plans, or timelines as agreed upon
• Prepare for follow-up meetings if further guidance is needed

All commitments and clarifications should be traceable in the IND submission history and eCTD sequence.

Global Variations in Regulatory Engagement

While the FDA’s Type B meeting structure is well-defined, other regulatory agencies offer similar scientific advice or pre-submission meetings:

• EMA: Scientific Advice Procedures
• PMDA (Japan): Clinical Trial Consultation
• TGA (Australia): Pre-submission meetings for clinical trial applications

Regulatory teams should align global development plans with feedback from multiple authorities to ensure harmonization.

Conclusion: Maximizing Value from Your Type B FDA Meeting

A Type B meeting with the FDA is a powerful regulatory milestone that can accelerate drug development, clarify expectations, and de-risk clinical programs. Success depends on strategic planning, precision in communication, and structured documentation.

By crafting a focused agenda, asking high-value questions, and aligning internally, sponsors can turn FDA meetings into catalysts for forward momentum. Thorough meeting preparation is not just best practice — it’s a regulatory imperative.